DSP Neamt informs that the new antiCovid vaccine is available free of charge and can be obtained through family doctors. “The Ministry of Health has announced the availability of the new Comirnaty Original/Omicron BA.4-5 vaccine for all eligible people who wish to be vaccinated.
The vaccine will be distributed to family medicine practices upon request
them, depending on the number of requests.
This vaccine is an adapted version of Comirnaty’s COVID-19 mRNA vaccine
(Pfizer/BioNTech) and targets the Omicron BA.4 and BA.5 subvariants in addition to the strain
original of SARS-CoV-2.
The vaccine causes the immune system (the body’s natural defense system) to
produce antibodies and blood cells, which act against the virus, thus providing
protection against the disease COVID 19.
The vaccine is only indicated for people, aged 12 years and over, who have previously received at least one primary vaccination schedule against the disease COVID
19 (one dose of Janssen – Johnson&Johnson vaccine or 2 doses of vaccine based on
mRNA – Comirnaty – Pfizer BioNTech or Spikevax – Moderna), at least 3 months after
the most recent dose of the vaccine against COVID 19.
Comirnaty Original/Omicron BA.4-5 is not recommended for children under 12 years of age.
Since the vaccine does not contain the virus to produce immunity, it cannot transmit
the disease COVID 19.
Those wishing to contact their family doctor to find out how they can get vaccinated at the office!
Vaccination is safe, voluntary and free!“, it is shown in a DSP Neamt press release.
Comirnaty Original/Omicron BA.4-5 should not be given to people allergic to
the active substance or any of the other components of this medicine.
As with any vaccine, it is possible for Comirnaty Original/Omicron BA.4-5 to
it does not fully protect all people to whom it is administered, and it is not known how much
time you will be protected.
The effectiveness of the vaccine may be lower in immunocompromised individuals. Discuss
with your doctor about appropriate individual recommendations.
Like all vaccines, Comirnaty Original/Omicron BA.4-5 can cause reactions
adverse effects, although they do not occur in all people.
Very common side effects (may affect more than 1 in 10 people):
• at the injection site: pain, swelling
• muscle pain
• joint pains
Some of these side effects were slightly more common in older adolescents
between 12 and 15 years than in adults.
Common side effects (may affect up to 1 in 10 people):
• redness at the injection site
Uncommon side effects (may affect up to 1 in 100 people):
• enlargement of the lymph nodes (observed more frequently after the booster dose)
• feeling sick
• pain in the arm
• itching at the injection site
• allergic reactions, eg rash or itching
• feeling weak or lack of energy/sleepiness
• loss of appetite
• excessive sweating
• night sweats
Rare side effects (may affect up to 1 in 1,000 people):
• Temporary “falling” of the face, on one side
• allergic reactions, for example hives or swelling of the face
Very rare side effects (may affect up to 1 in 10,000 people):
• inflammation of the heart muscle (myocarditis) or inflammation of the lining of the heart
(pericarditis), which may lead to difficulty breathing, palpitations or pain in the
Not known (frequency cannot be estimated from the available data)
• severe allergic reaction
• extensive swelling in the vaccinated limb
• swelling of the face (swelling of the face may occur in patients who
have previously received dermal filler injections in the face)
• a skin reaction that causes red dots or spots on the skin, which may stink
look like a target or ‘bull’s eye’ with a dark red center surrounded by paler red rings (erythema polymorphosis)
• unusual sensation on the skin, such as tingling or pricking (paraesthesia)
• reduced sensation or sensitivity, especially on the skin (hypoaesthesia)
• Adverse reaction reporting
If you experience any side effects, contact your doctor.
These include any possible side effects not mentioned in this leaflet. Of
you can also report adverse reactions directly through the national system
of reporting (see details below):
National Agency of Medicines and Medical Devices from Romania
Str. Aviator Sănătescu no. 48, sector 1 Bucharest 011478- RO e-mail: [email protected]
Website: www.anm.ro and include the series/lot, if available. By reporting side effects, you can help provide additional information on its safety